Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dipak R Patel

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Cellular Immunology|May 7, 2005
Constitutive expression of CIITA directs CD4 T cells to produce Th2 cytokines in the thymusDipak R Patel, Wei Li, Jae-Seung Park, et al.
Journal of the American Academy of Dermatology|October 8, 2025
A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativaSeth Forman, Dipak R Patel, Alexa B Kimball, et al.
The Journal of Experimental Medicine|August 29, 2007
Thymic selection pathway regulates the effector function of CD4 T cellsWei Li, M Hanief Sofi, Norman Yeh, et al.
Dermatology and Therapy|May 2, 2026
Understanding Social Drivers of Health, Burden, and Impact of Hidradenitis Suppurativa among Different Racial and Ethnic Groups in the USATarannum Jaleel, Raj Chovatiya, Elizabeth D Bacci, et al.
Clinical and Translational Science|December 31, 2020
Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjectsDipak R Patel, Shweta Urva, Stephen Ho, et al.
Open Forum Infectious Diseases|May 2, 2022
Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 TrialPeter Chen, Gerhard Behre, Corey Hebert, et al.
Infectious Diseases and Therapy|June 17, 2023
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 TrialHimanshu P Upadhyaya, Jenny Y Chien, Amanda J Long, et al.
Frontiers in Immunology|December 27, 2021
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab TogetherLin Zhang, Josh Poorbaugh, Michael Dougan, et al.
The New England Journal of Medicine|October 28, 2020
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19Peter Chen, Ajay Nirula, Barry Heller, et al.
JAMA|January 21, 2021
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical TrialRobert L Gottlieb, Ajay Nirula, Peter Chen, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Cellular Immunology|May 7, 2005
Constitutive expression of CIITA directs CD4 T cells to produce Th2 cytokines in the thymusDipak R Patel, Wei Li, Jae-Seung Park, et al.
Journal of the American Academy of Dermatology|October 8, 2025
A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativaSeth Forman, Dipak R Patel, Alexa B Kimball, et al.
The Journal of Experimental Medicine|August 29, 2007
Thymic selection pathway regulates the effector function of CD4 T cellsWei Li, M Hanief Sofi, Norman Yeh, et al.
Dermatology and Therapy|May 2, 2026
Understanding Social Drivers of Health, Burden, and Impact of Hidradenitis Suppurativa among Different Racial and Ethnic Groups in the USATarannum Jaleel, Raj Chovatiya, Elizabeth D Bacci, et al.
Clinical and Translational Science|December 31, 2020
Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjectsDipak R Patel, Shweta Urva, Stephen Ho, et al.
Open Forum Infectious Diseases|May 2, 2022
Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 TrialPeter Chen, Gerhard Behre, Corey Hebert, et al.
Infectious Diseases and Therapy|June 17, 2023
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 TrialHimanshu P Upadhyaya, Jenny Y Chien, Amanda J Long, et al.
Frontiers in Immunology|December 27, 2021
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab TogetherLin Zhang, Josh Poorbaugh, Michael Dougan, et al.
The New England Journal of Medicine|October 28, 2020
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19Peter Chen, Ajay Nirula, Barry Heller, et al.
JAMA|January 21, 2021
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical TrialRobert L Gottlieb, Ajay Nirula, Peter Chen, et al.
Pageof 3